SCHEMBL528860

SCHEMBL528860

CN(C)C(On1nnc2ccccc2c1=O)=[N+](C)C.F[B-](F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
HPSE Q9Y251 1/20 0.42
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HPGD P15428 3/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
CYP3A4 P08684 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
NPC1 O15118 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29354503 1.00 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2CYP1A2CYP2C19HPSE
SCHEMBL3127639 0.95 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2CYP1A2CYP2C19HPSE
SCHEMBL29357885 0.93 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2CYP1A2CYP2C19HPSE
SCHEMBL22262037 0.93 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2CYP1A2CYP2C19HPSE
SCHEMBL5379720 0.92 MAPK1 (0.42) ALDH1A1SMN1; SMN2CYP1A2CYP2C19HPSE
SCHEMBL2421131 0.91 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2CYP1A2CYP2C19HPSE
SCHEMBL5378097 0.89 HPSE (0.38) ALDH1A1SMN1; SMN2CYP1A2CYP2C19HPSE
SCHEMBL29475392 0.83 BRD4 (0.32) ALDH1A1GAA
SCHEMBL16765694 0.83 SIRT2 (0.45) ALDH1A1SMN1; SMN2KMT2ATSHRHPGD
SCHEMBL29361802 0.83 SIRT2 (0.45) ALDH1A1SMN1; SMN2KMT2ATSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-12508321-B2 Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers HANGZHOU DAC BIOTECH CO., LTD. (CN) 2025-12-30 US claimed
US-12496351-B2 Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers HANGZHOU DAC BIOTECH CO., LTD. (CN) 2025-12-16 US claimed
EP-4622991-A2 SYNTHESIS OF A CYCLIC PEPTIDE Janssen Pharmaceutica NV (BE) 2025-10-01 EP claimed
EP-4619408-A1 THE SYNTHESIS OF OMAPATRILAT Endothelium Scanning Nanotechnology Limited (AU) 2025-09-24 EP claimed
WO-2025119223-A1 METHOD FOR SYNTHESIZING AMANITIN AND DERIVATIVE THEREOF 上海皓元生物医药科技有限公司 2025-06-12 WO claimed
WO-2024256574-A1 PROCESS FOR PREPARING MACROCYCLIC BTK INHIBITORS CROSSFIRE ONCOLOGY HOLDING B.V. (NL) 2024-12-19 WO claimed
US-20240351989-A1 PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF ALIVUS LIFE SCIENCES LIMITED (IN) 2024-10-24 US claimed
EP-4384501-A1 PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF Glenmark Life Sciences Limited (IN) 2024-06-19 EP claimed
WO-2024110477-A2 SYNTHESIS OF A CYCLIC PEPTIDE JANSSEN PHARMACEUTICA NV (BE) 2024-05-30 WO claimed
US-20070093663-A1 Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof. LES LABORATOIRES SERVIER (FR) 2007-04-26 US claimed
US-20060135759-A1 Reusable universal polymer support for repetitive oligonucleotide synthesis COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH 2006-06-22 US claimed
EP-1436284-B1 SYNTHESIS OF 4- (Z)-(4-BROMOPHENYL)(ETHOXYIMINO)METHYL]-1'- 2,4-DIMETHYL-1-OXIDO-3-PYRIDINYL)CARBONYL]-4'METHYL-1,4'BIPIPERIDINE SCHERING CORP (US) 2005-08-03 EP claimed
US-6818773-B2 AIDS THERAPY; ANTIINFLAMAMTORY AGENTS; ANTIALLERGENS; RHEUMATIC DISEASES SCHERING CORPORATION 2004-11-16 US claimed
WO-2003033490-A9 SYNTHESIS OF 4-[(Z)-(4-BROMOPHENYL)(ETHOXYIMINO)METHYL]-1'-[2,4-DIMETHYL-1-OXIDO-3-PYRIDINYL)CARBONYL]-4'METHYL-1,4'BIPIPERIDINE SCHERING CORP (US) 2004-06-10 WO claimed
US-20040077878-A1 Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents LIU CHUNJIAN (US) 2004-04-22 US claimed
US-20030105131-A1 Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl]-4'-methyl-1,4-'bipiperidine SCHERING CORPORATION 2003-06-05 US claimed
EP-1091972-A1 REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) 2001-04-18 EP claimed
US-6015895-A REACTING A LINKER COMPOUND WITH A HYDROXY GROUP OF A NUCLEOSIDE AND A SOLID SUPPORT CAPABLE OF ESTERIFICATION; LINKER IS STABILE AGAINST SPONTANEOUS HYDROLYSIS AND EASILY CLEAVED WHEN NECESSARY UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) 2000-01-18 US claimed
WO-2000001711-A1 REUSABLE SOLID SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS UNIVERSITY TECHNOLOGIES INTERNATIONAL INC. (CA) 2000-01-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12508321-B2 Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers CD4, CD2, B2M ALDH1A1 2817/4885SMN1; SMN2 4564/4885CYP1A2 4777/4885
US-20240351989-A1 PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF PARP1, PARP2, PARP4 ALDH1A1 1541/4885SMN1; SMN2 3917/4885CYP1A2 590/4885
US-12496351-B2 Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers CD2BP2, DCLRE1A, EPCAM ALDH1A1 618/4885SMN1; SMN2 4501/4885CYP1A2 4497/4885
US-20030105131-A1 Synthesis of 4-[(Z)-4-bromophenyl)(ethoxyimino) methyl]-1'-[(2,4-dimethyl-1-oxido-3-pyridinyl)carbonyl]-4'-methyl-1,4-'bipiperidine DNMT1, BCDIN3D, TET1 ALDH1A1 140/4885SMN1; SMN2 2257/4885CYP1A2 216/4885
US-20070093663-A1 Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof. QDPR, REN, ACE ALDH1A1 82/4885SMN1; SMN2 1770/4885CYP1A2 56/4885
US-20040077878-A1 Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents IMPDH1, IMPDH2, HNMT ALDH1A1 1115/4885SMN1; SMN2 4681/4885CYP1A2 2020/4885
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS DCLRE1A, CCR3, CCR8 ALDH1A1 2641/4885SMN1; SMN2 4051/4885CYP1A2 4265/4885
US-20060135759-A1 Reusable universal polymer support for repetitive oligonucleotide synthesis POLI, PCNA, POLN ALDH1A1 4169/4885SMN1; SMN2 2305/4885CYP1A2 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.